Latest Digestion News
- Dialysis Patients: Weak Response to COVID Vaccine
- Are You Eating Foods That Harm Your 'Microbiome'?
- Cycling During Dialysis? It Might Help Patients
- Sluggish Coworker? Maybe They 'Pigged Out' Before
- Can a Yeast Found in Cheese Ease Crohn's Disease?
- Want More News? Sign Up for MedicineNet Newsletters!
MONDAY, Dec. 9, 2013 (HealthDay News) -- Sovaldi (sofosbuvir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with Hepatitis C. It's considered a breakthrough medication since it's the first such drug that does not require same-time administration of interferon, the agency said in a news release.
Infection with the hepatitis C virus causes liver inflammation that can lead to liver failure. Most infected people have no symptoms for years until the onset of liver failure, the FDA said. Complications may include a yellowing of the eyes and skin called jaundice, liver cancer, bleeding or fluid accumulation in the abdomen. Some 3.2 million Americans are infected with hepatitis C, the agency said.
Sovaldi is designed to inhibit a protein that the virus needs to replicate. The drug's safety and effectiveness were evaluated in clinical studies involving 1,947 people who hadn't responded to other hepatitis C treatments, who hadn't been treated previously, or who couldn't tolerate the standard treatment of interferon, the FDA said.
-- Scott Roberts
Copyright © 2013 HealthDay. All rights reserved.